Economic evaluation of Qili Qiangxin capsules for the treatment of chronic heart failure

Abstract

Introduction Chronic heart failure (CHF) confers high mortality and heavy economic burden as a critical public health issue. Qili Qiangxin (QLQX) capsules, a traditional Chinese patent medicine, may improve clinical outcomes in CHF patients. This study evaluated the economic value of QLQX capsules for CHF. Methods A health economic analysis was performed from the healthcare system perspective. Cost-effectiveness analysis was used for short-term outcomes, and a Markov model-based cost-utility analysis for long-term outcomes. Robustness was tested using one-way and probabilistic sensitivity analyses. Results A total of 1555 patients were equally randomized to two groups: QLQX capsules plus standard of care (QLQX group) or standard of care alone (control group). Baseline characteristics were comparable between groups. In the QLQX group, 1-year direct medical costs were ¥9368.08 (\$1311.53; 95% confidence interval [CI]: [¥8980.61, ¥9755.55]), versus ¥6402.21 (\$896.31; 95% CI: [¥5903.50, ¥6900.91]) in the control group. The higher costs in the QLQX group were primarily driven by medication expenses. Composite endpoint events occurred in 19.00% (95% CI: [17.07%, 21.03%]) of the QLQX group compared with 23.40% (95% CI: [21.34%, 25.61%]) of the control group (P = 0.003). The incremental cost-effectiveness ratio (ICER) was ¥67 406.14 (\$9436.86). Over a 15-year time horizon, the QLQX group incurred total costs of ¥57 096 (\$7993.44) and achieved 5.46 QALYs, whereas the control group incurred ¥34 016 (\$4762.24) and achieved 5.07 QALYs, resulting in an ICER of ¥58 946 per QALY (\$8252.44/QALY). This value is below China’s 2023 per capita gross domestic product threshold (¥89 358; \$12 510.12), suggesting that QLQX capsule is highly cost-effective. Sensitivity analyses further confirmed the robustness of these findings. Conclusion QLQX capsules were associated with higher short-term costs but greater efficacy than standard care, and long-term modeling supports their high cost-effectiveness.

Keywords

Qili Qiangxin capsules / chronic heart failure / pharmacoeconomics / cost-effectiveness analysiscost-utility analysis

References

[1] Forouzanfar MH, Moran A, Phillips D, et al. Prevalence of heart failure by cause in 21 regions: global burden of diseases, injuries and risk factors- 2010 study. J Am Coll Cardiol. 2013; 61(10):E786.

[2] McCormack PL. Sacubitril/valsartan: a review in chronic heart failure with reduced ejection fraction. Drugs. 2016; 76(3):387-396.

[3] Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022; 145(18):e895-e1032.

[4] Gu DF, Huang GY, He J, et al.Investigation of prevalence and distributing feature of chronic heart failure in Chinese adult population. Chin J Cardiol. 2003; 31(1):3-6.

[5] Wang H, Chai K, Du M, et al. Prevalence and incidence of heart failure among urban patients in china: a national population-based analysis. Circ Heart Fail. 2021; 14(10):e008406.

[6] Cook C, Cole G, Asaria P, Jabbour R, Francis DP. The annual global economic burden of heart failure. Int J Cardiol. 2014; 171(3):368-376.

[7] McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42(36):3599-3726.

[8] McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019; 381(21):1995-2008.

[9] Li X, Zhang J, Huang J, et al. A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of Qili Qiangxin capsules in patients with chronic heart failure. J Am Coll Cardiol. 2013; 62(12):1065-1072.

[10] Ji XD, Yang D, Cui XY, et al. Mechanism of Qili Qiangxin capsule for heart failure based on miR133a-endoplasmic reticulum stress. Chin J Integr Med. 2024; 30(5):398-407.

[11] Cheang I, Yao W, Zhou Y, et al. The traditional Chinese medicine Qiliqiangxin in heart failure with reduced ejection fraction: a randomized, double-blind, placebo-controlled trial. Nat Med. 2024; 30(8):2295-2302.

[12] Liu GN, Wu J, Xie F, Sun X, Li HC, Guan HJ. Chinese Guidelines for Pharmacoeconomic Evaluations: A Manual (2022). Beijing: China Market Press; 2022.

[13] National Bureau of Statistics. Statistical communiqué of the People’s Republic of China on the 2023 national economic and social development. https://www.stats.gov.cn/sj/zxfb/202402/t20240228_1947915.html. Accessed March 20, 2025.

[14] Cohen LP, Isaza N, Hernandez I, et al. Cost-effectiveness of sodium-glucose cotransporter-2 inhibitors for the treatment of heart failure with preserved ejection fraction. JAMA Cardiol. 2023; 8(5):419.

[15] Yu DS, Li PW, Li SX, Smith RD, Yue SC, Yan BPY. Effectiveness and cost-effectiveness of an empowerment-based self-care education program on health outcomes among patients with heart failure: a randomized clinical trial. JAMA Netw Open. 2022; 5(4):e225982.

[16] National Bureau of Statistics.Annual data. https://data.stats.gov.cn/easyquery.htm?cn=C01&zb=A0301&sj=2025. Accessed March 20, 2025.

[17] Chen C, Wu H, Zhou J, et al. Pharmacoeconomics of ivabradine in the treatment of CHF in the context of “Quadruple Therapy”. China Pharm. 2024; 35(1):63-68.

[18] Zhao Q, Li H, Chang L, et al. Qiliqiangxin attenuates oxidative stress-induced mitochondrion-dependent apoptosis in cardiomyocytes via PI3K/AKT/GSK3β signaling pathway. Biol Pharm Bull. 2019; 42(8):1310-1321.

[19] Li F, Wang J, Song Y, et al. Qiliqiangxin alleviates Ang II-induced CMECs apoptosis by downregulating autophagy via the ErbB2-AKT-FoxO3a axis. Life Sci. 2021; 273:119239.

[20] Li Y, Zhang Z, Hao X, Yu T, Li S. Qiliqiangxin capsule modulates calcium transients and calcium sparks in human induced pluripotent stem cell-derived cardiomyocytes. Evid Based Complement Alternat Med. 2022; 2022:9361077.

[21] Packer M. Qiliqiangxin: a multifaceted holistic treatment for heart failure or a pharmacological probe for the identification of cardioprotective mechanisms? Eur J Heart Fail. 2023; 25(12):2130-2143.

[22] Wang Y, Fu M, Wang J, et al. Qiliqiangxin improves cardiac function through regulating energy metabolism via HIF-1α-dependent and independent mechanisms in heart failure rats after acute myocardial infarction. Biomed Res Int. 2020; 2020:1276195.

[23] Sun X, Chen G, Xie Y, et al. Qiliqiangxin improves cardiac function and attenuates cardiac remodelling in doxorubicin-induced heart failure rats. Pharm Biol. 2020; 58(1):417-426.

[24] Chen W, Chang H, Wang X, Wang Y, Liu Y, Wang D. The efficacy and safety of a Qiliqiangxin capsule combined with sacubitril/valsartan in the treatment of chronic heart failure: a systematic review and meta-analysis. Evid Based Complement Alternat Med. 2023; 2023:2701314.

[25] Gerber Y, Weston SA, Redfield MM, et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med. 2015; 175(6):996.

[26] Zarrinkoub R, Wettermark B, Wändell P, et al. The epidemiology of heart failure, based on data for 2.1 million inhabitants in Sweden. Eur J Heart Fail. 2013; 15(9):995-1002.

[27] Wang Z, Chi HJ, Lin XM, et al. Analysis of long-term mortality and influencing factors in patients with chronic heart failure. Chin J Med. 2021; 56(6):639-642.